[Treatment-resistant bacterial infection in specific bacterial species and developmental movement of new antibiotics--Mycobacterium].
Mycobacterium tuberculosis and atypical mycobacteriosis are potent diseases which had not been curable before. Progress of chemotherapy has a marked effect but not enough results. We are now waiting for the appearance of a new medicine. Other rifamycim derivatives are developed as antimycobacterial agents, which have a mainframe of 3'-hydroxy-5'-alkylpiperazinyl-benzoxazinorifamycins (KRMs). KRMs exceeds RFP in bacteriostatic function, and also have already established in vivo in chemotherapeutic efficacy. Another study will also reveal a higher of bactericidal function. We expect possibility of much more powerful and short-term initial chemotherapy.
Shiraishi
T
T
1st Department of Medicine, Kurume University School of Medicine.
Ichikawa
Y
Y
Oizimi
K
K
D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents